LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia
29 avr. 2019 08h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide™ Platform Development and Advancement of Lead Program into Clinic
22 avr. 2019 08h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
01 avr. 2019 08h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
LogicBio Therapeutics to Present at Upcoming March Conferences
25 févr. 2019 07h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development
22 févr. 2019 07h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors
06 déc. 2018 08h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio Reports Third Quarter 2018 Financial Results
03 déc. 2018 08h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
LogicBio Announces Partnership with Children’s Medical Research Institute to Develop Next Generation Viral Vectors
15 nov. 2018 06h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ: LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio to Present at the Jefferies 2018 London Healthcare Conference
13 nov. 2018 08h00 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients...
LogicBio Therapeutics Announces Closing of Initial Public Offering
23 oct. 2018 16h05 HE
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients...